Wall Street Beat
iRadimed sets terms for $10M IPO
iRadimed today set the range for its forthcoming initial public offering at $5 to $6 per share.
Winter Springs, Fla.-based iRadimed said it plans to issue 1.75 million shares in the IPO, making the offering worth between $8.75 million and $10.5 million.
Philips Healthcare retools, CEO DiSanzo is out
T2 Biosystems prepares $69M IPO for MRI-based diagnostics
Diagnostics-maker T2 Biosystems is preparing to go public in an offering that could garner as much as $69 million, according to SEC filings.
Ex-Biolase CEO isn’t giving up without a fight
Report: Another activist investor pressures Allergan to sell
Wright Medical unveils Infinity total ankle replacement system in the U.S. | Medtech Wall Street news for the week of June 23, 2014
Lantheus Medical plots IPO worth up to $125M
Massachusetts-based Lantheus Medical Imaging announced today that it filed registration documents ahead of launching an initial public offering.
The company, which makes imaging agents and other diagnostic products, has yet to reveal share pricing or quantity, but set the maximum aggregate offering price at $125 million. Lantheus deals primarily in radiopharmaceutical and contrast agents, according to the prospectus summary.
Medical Action shares nearly double on news of $208M Owens & Minor acquisition
CareFusion hits new high, confirms layoffs and outsourcing to Mexico
Updated 6/24/2014 at 5:20 p.m. EST with comments from CareFusion.